Lannett Announces Revised FDA PDUFA Date for Morphine Sulfate Oral Solution NDA

Lannett Company, Inc. LCI announced today that the U.S. Food and Drug Administration has issued a revised Prescription Drug User Fee Act goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution. “With a revised PDUFA date in 17 days, we are preparing for the re-launch of our Morphine Sulfate Oral Solution product, if approved,” said Arthur Bedrosian, president and chief executive officer of Lannett.